Genetic and pharmacologic evidence implicating the p85α, but not p85β, regulatory subunit of PI3K and Rac2 GTPase in regulating oncogenic KIT-induced transformation in acute myeloid leukemia and systemic mastocytosis
Open Access
- 1 September 2007
- journal article
- Published by American Society of Hematology in Blood
- Vol. 110 (5) , 1612-1620
- https://doi.org/10.1182/blood-2006-10-053058
Abstract
Oncogenic activation loop KIT mutations are observed in acute myeloid leukemia (AML) and systemic mastocytosis (SM); however, unlike the KIT juxtamembrane mutants, the activation loop mutants are insensitive to imatinib mesylate. Furthermore, as prior studies primarily used heterologous cell lines, the molecular mechanism(s) underlying oncogenic KIT-induced transformation in primary cells is poorly understood. We demonstrate that expression of KITD814V in primary hematopoietic stem/progenitor cells (HSC/Ps) and mast cell progenitors (MCps) induces constitutive KIT autophosphorylation, supports ligand-independent hyperproliferation, and promotes promiscuous cooperation with multiple cytokines. Genetic disruption of p85α, the regulatory subunit of class IA lipid kinase phosphoinositol-3-kinase (PI3K), but not of p85β, or genetic disruption of the hematopoietic cell-specific Rho GTPase, Rac2, normalizes KITD814V-induced ligand-independent hyperproliferation. Additionally, deficiency of p85α or Rac2 corrects the promiscuous hyperproliferation observed in response to multiple cytokines in both KITD814V-expressing HSC/Ps and MCps. Treatment of KITD814V-expressing HSC/Ps with a Rac inhibitor (NC23766) or with rapamycin showed a dose-dependent suppression in ligand-independent growth. Taken together, our results identify p85α and Rac2 as potential novel therapeutic targets for the treatment of KITD814V-bearing AML and SM.Keywords
This publication has 55 references indexed in Scilit:
- Rapamycin inhibits growth and survival of D816V-mutated c-kit mast cellsBlood, 2006
- Kit-activating mutations cooperate with Spi-1/PU.1 overexpression to promote tumorigenic progression during erythroleukemia in miceCancer Cell, 2005
- Mutations in the receptor tyrosine kinase pathway are associated with clinical outcome in patients with acute myeloblastic leukemia harboring t(8;21)(q22;q22)Leukemia, 2005
- c-Kit-Mediated Overlapping and Unique Functional and Biochemical Outcomes via Diverse Signaling PathwaysMolecular and Cellular Biology, 2004
- Genetic evidence for convergence of c-Kit– and α4 integrin–mediated signals on class IA PI-3kinase and the Rac pathway in regulating integrin-directed migration in mast cellsBlood, 2003
- Necessity of tyrosine 719 and phosphatidylinositol 3′-kinase–mediated signal pathway in constitutive activation and oncogenic potential of c-kit receptor tyrosine kinase with the Asp814Val mutationBlood, 2003
- STAT3 activation is required for Asp816 mutant c-Kit induced tumorigenicityOncogene, 2001
- Kit/stem cell factor receptor-induced activation of phosphatidylinositol 3′-kinase is essential for male fertilityNature Genetics, 2000
- Xid -Like Immunodeficiency in Mice with Disruption of the p85α Subunit of Phosphoinositide 3-KinaseScience, 1999
- Gain-of-Function Mutations of c- kit in Human Gastrointestinal Stromal TumorsScience, 1998